Assessment of Interactions Between Methamphetamine and Aripiprazole - 1

Assessment of Interactions Between IV Methamphetamine and Aripiprazole

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00089440

Enrollment

Registered

2004-08-06

Start date

2004-06-30

Completion date

2005-03-31

Last updated

2017-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amphetamine-Related Disorders

Brief summary

The purpose of this study is to assess the interactions between intravenous methamphetamine and aripiprazole.

Detailed description

This is a double-blind, placebo-controlled human laboratory clinical pharmacology study to assess potential interactions between intravenous d-methamphetamine infusion and treatment with oral aripiprazole.

Interventions

DRUGAripiprazole

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* Must meet DSM-4 criteria for methamphetamine abuse or dependence and are non-treatment seeking. * Ability to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures.

Exclusion criteria

* Please contact the site for more information.

Design outcomes

Primary

Measure	Time frame
Adverse effect measures	—
pharmacokinetic assessment	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026